Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
about
Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantationFenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanomaPreclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.High-dose fenretinide in oral leukoplakia.Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide.Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposureDevelopment and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer.Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo.Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.Combination therapies improve the anticancer activities of retinoids in neuroblastoma.
P2860
Q24186451-5E8C979B-A94A-49BE-8FE4-486C14817D41Q33424045-12724199-EFC9-4CD5-88C5-D67B4EDC1E9FQ34051168-FC96E5F8-372B-4807-8150-F3D6B797E474Q34055511-F14F4651-191A-40E6-AB3A-3144D0845A3EQ34164825-848C3D99-6B73-4551-A78E-EFBB8D5DCDE1Q34182665-01550EE3-25AD-4BF9-B807-F9E08AEAAEB5Q34344093-2F203D27-1F25-459F-94A8-794EA24E1213Q34588717-0FBA3ECE-5DDA-44B3-A804-7A26DBA880E7Q35130547-3EAF2F15-9246-4C9A-8DE9-DF2F21FF72F3Q35209424-B375F0C8-61E7-4C9E-BA66-B50D33CEC8DCQ36449459-204DCDC7-C915-4C3A-AAE1-7899918A3673Q38608663-89CA5BF5-FCC8-4E62-B9C0-47D512909E67Q38876333-65E0949C-E211-4649-8CDF-EB8EF3128E7EQ43134812-D77984A9-7917-449E-AADF-F81FC071F00F
P2860
Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pharmacokinetics of oral fenre ...... metabolite 4-oxo-fenretinide.
@en
type
label
Pharmacokinetics of oral fenre ...... metabolite 4-oxo-fenretinide.
@en
prefLabel
Pharmacokinetics of oral fenre ...... metabolite 4-oxo-fenretinide.
@en
P2093
P50
P1476
Pharmacokinetics of oral fenre ...... metabolite 4-oxo-fenretinide.
@en
P2093
Elena Cavadini
Franca Formelli
Maria Grazia Villani
Stefano Persiani
P2888
P304
P356
10.1007/S00280-007-0649-7
P577
2007-12-08T00:00:00Z
P6179
1024095051